49 results
Page 2 of 3
8-K
EX-99.1
pvap2i0kvcc8
24 Feb 21
Sage Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business Progress
6:46am
8-K
EX-99.1
7bctbc 8l
1 Oct 20
Sage Therapeutics Appoints Barry Greene to Board of Directors
4:05pm
8-K
EX-1.1
smma0b16plfmi 9t6vlq
27 Feb 19
Sage Therapeutics Announces Proposed Public Offering of Common Stock
8:08am
8-K
EX-99.1
84998d 9wljy
23 Jan 19
Sage Therapeutics Appoints Elizabeth Barrett and George Golumbeski to Board of Directors
5:03pm
8-K
EX-99.1
qa3a9pf4 f0cpwp
12 Jun 18
Sage Announces Pivotal Phase 3 Trial Status forSAGE-217 in Major Depressive Disorder and Postpartum
7:30am
8-K
EX-99.1
3jh ooveyj6xm7rex6
30 May 18
Sage Therapeutics Announces FDA Acceptance of NDA Filing and Grant of Priority Review for Brexanolone IV in the Treatment of Postpartum Depression
7:30am
10-K
m1oc0o2qrxc4l46xeu
6 Mar 15
Annual report
12:00am
424B4
upthd2
18 Jul 14
Prospectus supplement with pricing info
12:00am